IDEXX Laboratories Q2 2024 Adj. EPS $3.02 Beats $2.88 Estimate, Sales $1.004B Miss $1.007B Estimate
Portfolio Pulse from Benzinga Newsdesk
IDEXX Laboratories reported Q2 2024 adjusted EPS of $3.02, beating the estimate of $2.88. However, sales came in at $1.004 billion, slightly missing the estimate of $1.007 billion.
August 06, 2024 | 10:31 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
IDEXX Laboratories reported mixed Q2 2024 results with EPS beating estimates but sales slightly missing expectations.
The mixed results, with EPS beating estimates but sales missing slightly, are likely to have a neutral short-term impact on IDXX's stock price. Investors may weigh the positive EPS against the slight sales miss.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100